Atrial Cardiomyopathy (ACM) has emerged as an important clinical entity with significant impacts on prognosis. It has been characterized as atrial enlargement, atrial arrhythmia and thrombogenesis. Atrial fibrosis accounts for the major pathophysiological mechanism of ACM, which could be assessed by late gadolinium-enhancement of magnetic resonance. However, the definition of ACM is lack of consensus.
ACM is also strongly correlated with atrial fibrillation, the most common sustained arrhythmia. The increased accessibility of long-term heart rhythm monitoring has revealed that in patients with paroxysmal atrial fibrillation, during the sinus rhythm periods, thromboembolism still occurs. This phenomenon provokes the notion that ACM is probably the underlying chain that links atrial arrhythmia (atrial fibrillation, premature atrial beats, comprehensive atrial flutter), atrial thrombogenesis and impaired atrial systolic and diastolic function. The progression of atrial fibrillation is also aligned with that of ACM, suggesting that they are the two-sides of a coin.
Comprehensive management strategies are warranted based on the identification and severity assessment of ACM. These strategies may include anti-arrhythmia, anticoagulation and upstream therapy, etc. While these perspectives of ACM are still under investigation.
In this Research Topic, we would like to create a forum focusing on current advances concerning the identification, definition, risk evaluation, management strategy, and new notions on ACM. The major perspectives would include, but not limited to:
1) Providing new insights on the clinical manifestation and diagnostic criteria for ACM that relies on repeatable and non-invasive approaches, including methods that reflect structural, functional, or electrophysiological anomalies of the atrium.
2) Illustrating the clinical or pathophysiological mechanisms of the development and progression of ACM.
3) Analyzing the relationship between ACM and atrial fibrillation, including disease progression, risk assessment, and ablation strategy.
4) Assessing current management strategies of ACM, such as anticoagulation, antiarrhythmics, and upstream treatment and the effectiveness evaluation.
5) Exploring the role of artificial intelligence in the identification and prediction of ACM.
6) Prognosis of ACM and related clinical outcomes.
7) Mechanism of ACM and it’s progression.
Atrial Cardiomyopathy (ACM) has emerged as an important clinical entity with significant impacts on prognosis. It has been characterized as atrial enlargement, atrial arrhythmia and thrombogenesis. Atrial fibrosis accounts for the major pathophysiological mechanism of ACM, which could be assessed by late gadolinium-enhancement of magnetic resonance. However, the definition of ACM is lack of consensus.
ACM is also strongly correlated with atrial fibrillation, the most common sustained arrhythmia. The increased accessibility of long-term heart rhythm monitoring has revealed that in patients with paroxysmal atrial fibrillation, during the sinus rhythm periods, thromboembolism still occurs. This phenomenon provokes the notion that ACM is probably the underlying chain that links atrial arrhythmia (atrial fibrillation, premature atrial beats, comprehensive atrial flutter), atrial thrombogenesis and impaired atrial systolic and diastolic function. The progression of atrial fibrillation is also aligned with that of ACM, suggesting that they are the two-sides of a coin.
Comprehensive management strategies are warranted based on the identification and severity assessment of ACM. These strategies may include anti-arrhythmia, anticoagulation and upstream therapy, etc. While these perspectives of ACM are still under investigation.
In this Research Topic, we would like to create a forum focusing on current advances concerning the identification, definition, risk evaluation, management strategy, and new notions on ACM. The major perspectives would include, but not limited to:
1) Providing new insights on the clinical manifestation and diagnostic criteria for ACM that relies on repeatable and non-invasive approaches, including methods that reflect structural, functional, or electrophysiological anomalies of the atrium.
2) Illustrating the clinical or pathophysiological mechanisms of the development and progression of ACM.
3) Analyzing the relationship between ACM and atrial fibrillation, including disease progression, risk assessment, and ablation strategy.
4) Assessing current management strategies of ACM, such as anticoagulation, antiarrhythmics, and upstream treatment and the effectiveness evaluation.
5) Exploring the role of artificial intelligence in the identification and prediction of ACM.
6) Prognosis of ACM and related clinical outcomes.
7) Mechanism of ACM and it’s progression.
